2012


To access this material please log in or register

Register Authorize
2012/№3

Role of endothelium dysfunction in progressing of CHF. Possibilities of effective drug therapy with AII blocker Valsartan

Kukes V. G., Gyamdzgyan K. A., Maximov M. L.
State Budgetary Educational Institution “I. M. Sechenov First Moscow State Medical University” of the RF Ministry of Health Care, Trubetskaya 8, Bld. 2, Moscow 119991

Keywords: AII receptor antagonists, valsartan, endothelial dysfunction, therapy, CHF

DOI: 10.18087 / rhfj.2012.3.1686

Endothelial dysfunction is ascribed the exclusive role in buildup and progress of CHF. The expressed endothelial dysfunction in CHF is accounted for by hyperactivation of RAAS. Consequently, the pharmacological blockage of 1st type receptors to AII might be accompanied by correction of endothelyocyte function defects, which, in its turn, must account for subsequent reduction of the cardiovascular complications. One of the advantages of the angiotensin receptor blockers, in particular, Valsartan, is blockade of AII action in all tissues irrespective of the way of formation whereas ACEI don’t affect AII formation with the help of the tissue chymase. Experimental and clinical studies with participation of patients with cardiovascular pathology, including CHF, testified about the positive effect of Valsartan on function of the endothelyocytes, intraorgan blood flow and microcirculation, as well as on the level of microalbuminuria.
  1. Агеев Ф. Т., Арутюнов Г. П., Беленков Ю. Н. и др. Хроническая сердечная недостаточность. – М., «ГЭОТАР-Медиа», 2010. – 336с.
  2. Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med. 1993;153 (8):937–942.
  3. Фомин В. В. Блокаторы рецепторов ангиотензина II показаны большинству больных артериальной гипертензией? Доступно на: http://www.consilium-medicum.com / article / 17153
  4. Минушкина Л. О., Затейщиков Д. А. Станет ли валсартан препаратом первого ряда для лечения сердечной недостаточности? Фарматека. 2004;8:49–55.
  5. Максимов М. Л. Дербенцева Е. А., Дралова О. В. и др. Применение блокатора АТ1‑рецепторов ангиотензина II валсартана у пациентов с хронической сердечной недостаточностью. Журнал Сердечная недостаточность. 2010;11 (5):301–305.
  6. Максимов М. Л. Ермолаева А. С. Дралова О. В. Артериальная гипертония, ожирение, эректильная дисфункция. Какой препарат выбрать? Кардиология. 2011;51 (7):58–64.
  7. Кукес В. Г., Семенов А. В., Сычев Д. А., Проблемы взаимодействия лекарственных средств в кардиологической практике: антигипертензивные и гиполипидемические препараты. РМЖ. 2006;20:1423–1428.
  8. Оганов Р. Г., Масленникова Г. Я., Шальнова С. А. и др. Значение сердечно-сосудистых и других неинфекционных заболеваний для здоровья населения России. Профилактика забол и укрепл здор. 2002;2: 3–7.
  9. Cottone S, Vadala A, Mangano MT et al. Endothelium-derived factors in microalbuminuric and nonmicroalbuminuric essential hypertensives. Am J Hypertens. 2000;13 (2):172–176.
  10. Delles C, Schmieder RE. Renal endothelial effects of antihypertensive therapy. Curr Opin Nephrol Hypertens. 2004;13 (5):489–493.
  11. Remuzzi G, Weening JJ. Albuminuria as early test for vascular disease. Lancet. 2005;365 (9459):556–557.
  12. Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation. 2000;101 (14):1653–1659.
  13. Isobe N, Taniguchi K, Oshima S et al. Candesartan cilexetil improves left ventricular function, left ventricular hypertrophy, and endothelial function in patients with hypertensive heart disease. Circ J. 2002;66 (11):993–999.
  14. Inoue M, Fujii S, Taisei M et al. [Dilation of the brachial artery in response to sublingual nitroglycerin can predict the antihypertensive effects of valsartan: a study using novel high-frequency high-frame-rate ultrasound imaging]. J Cardiol. 2006;47 (1):9–14.
  15. Ikeda F, Azuma K, Ogihara T et al. Angiotensin II type 1 receptor blocker reduces monocyte adhesion to endothelial cells in spontaneously hypertensive rats. Endocr J. 2007;54 (4):605–612.
  16. Yamamoto E, Kataoka K, Shintaku H et al. Novel mechanism and role of angiotensin II induced vascular endothelial injury in hypertensive diastolic heart failure. Arterioscler Thromb Vasc Biol. 2007;27 (12):2569–2575.
  17. Su KH, Tsai JY, Kou YR et al. Valsartan regulates the interaction of angiotensin II type 1 receptor and endothelial nitric oxide synthase via Src / PI3K / Akt signalling. Cardiovasc Res. 2009;82 (3):468–475.
  18. de las Heras N, Aragoncillo P, Maeso R et al. AT (1) receptor antagonism reduces endothelial dysfunction and intimal thickening in atherosclerotic rabbits. Hypertension. 1999;34 (4 Pt 2):969–975.
  19. Gervais M, Richer C, Fornes P et al. Valsartan and coronary haemodynamics in early post-myocardial infarction in rats. Fundam Clin Pharmacol. 1999;13 (6):635–645.
  20. Higuchi T, Abletshauser C, Nekolla SG et al. Effect of the angiotensin receptor blocker Valsartan on coronary microvascular flow reserve in moderately hypertensive patients with stable coronary artery disease. Microcirculation. 2007;14 (8):805–812.
  21. Oubiña MP, de Las Heras N, Vázquez-Pérez S et al. Valsartan improves fibrinolytic balance in atherosclerotic rabbits. J Hypertens. 2002;20 (2):303–310.
  22. Klingbeil AU, John S, Schneider MP et al. Effect of AT1 receptor blockade on endothelial function in essential hypertension. Am J Hypertens. 2003;16 (2):123–128.
  23. Tzemos N, Lim PO, MacDonald TM. Valsartan improves endothelial dysfunction in hypertension: a randomized, double-blind study. Cardiovasc Ther. 2009;27 (3):151–158.
  24. Viberti G, Wheeldon NM. For the MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002;106 (6):672–678.
  25. Katayama S, Yagi S, Yamamoto H et al. Is renoprotection by angiotensin receptor blocker dependent on blood pressure?: the Saitama Medical School, Albuminuria Reduction in Diabetics with Valsartan (STAR) study. Hypertens Res. 2007;30 (6):529–533.
  26. Watanabe S, Okura T, Kurata M et al. Valsartan reduces serum cystatin C and the renal vascular resistance in patients with essential hypertension. Clin Exp Hypertens. 2006;28 (5):451–461.
Kukes V. G., Gyamdzgyan K. A., Maximov M. L. Role of endothelium dysfunction in progressing of CHF. Possibilities of effective drug therapy with AII blocker Valsartan. Russian Heart Failure Journal. 2012;13(3):184-187

To access this material please log in or register

Register Authorize
Ru En